Regulation of cytotoxic T-cell responses by p53 in cancer.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28944167)

Published in Transl Cancer Res on December 01, 2016

Authors

Mitchell W Braun1, Tomoo Iwakuma1

Author Affiliations

1: Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA.

Articles cited by this

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell (1997) 10.52

Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009) 3.39

MDM2, an introduction. Mol Cancer Res (2003) 2.87

p53: new roles in metabolism. Trends Cell Biol (2007) 2.69

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62

Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55

The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation. J Biol Chem (1999) 2.29

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother (2006) 1.81

In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med (2006) 1.79

Identification of MECL-1 (LMP-10) as the third IFN-gamma-inducible proteasome subunit. J Immunol (1996) 1.62

Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci (2012) 1.36

MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst (2013) 1.31

Crippling p53 activities via knock-in mutations in mouse models. Oncogene (2007) 1.19

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal (2014) 1.06

PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst (2015) 1.02

ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases. Mol Immunol (2013) 1.02

DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol (1994) 1.02

Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther (1998) 1.00

Insights into the molecular regulation of FasL (CD178) biology. Eur J Cell Biol (2010) 0.97

p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene (1999) 0.92

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer (2016) 0.85

p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat Commun (2013) 0.84

p53 potentiation of tumor cell susceptibility to CTL involves Fas and mitochondrial pathways. J Immunol (2005) 0.79

Articles by these authors

Unsaturated fatty acids regulate stemness of ovarian cancer cells through NF-κB. Stem Cell Investig (2017) 0.75